CN109793885B - Preparation method of composite polypeptide for preventing or relieving anemia - Google Patents
Preparation method of composite polypeptide for preventing or relieving anemia Download PDFInfo
- Publication number
- CN109793885B CN109793885B CN201910186658.9A CN201910186658A CN109793885B CN 109793885 B CN109793885 B CN 109793885B CN 201910186658 A CN201910186658 A CN 201910186658A CN 109793885 B CN109793885 B CN 109793885B
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- liquid
- plant
- enzymolysis
- composite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 128
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 106
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 104
- 239000002131 composite material Substances 0.000 title claims abstract description 56
- 208000007502 anemia Diseases 0.000 title claims abstract description 54
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000007788 liquid Substances 0.000 claims abstract description 64
- 210000004369 blood Anatomy 0.000 claims abstract description 47
- 239000008280 blood Substances 0.000 claims abstract description 47
- 102000001554 Hemoglobins Human genes 0.000 claims abstract description 45
- 108010054147 Hemoglobins Proteins 0.000 claims abstract description 45
- 239000000843 powder Substances 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 25
- 238000001914 filtration Methods 0.000 claims abstract description 22
- 102000004190 Enzymes Human genes 0.000 claims abstract description 19
- 108090000790 Enzymes Proteins 0.000 claims abstract description 19
- 229940088598 enzyme Drugs 0.000 claims abstract description 19
- 239000000463 material Substances 0.000 claims abstract description 19
- 235000018927 edible plant Nutrition 0.000 claims abstract description 17
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 15
- 150000004676 glycans Chemical class 0.000 claims abstract description 14
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 14
- 239000005017 polysaccharide Substances 0.000 claims abstract description 14
- 108010059892 Cellulase Proteins 0.000 claims abstract description 7
- 229940106157 cellulase Drugs 0.000 claims abstract description 7
- 230000003213 activating effect Effects 0.000 claims abstract description 6
- 241000196324 Embryophyta Species 0.000 claims description 39
- 239000000243 solution Substances 0.000 claims description 38
- 241000282994 Cervidae Species 0.000 claims description 23
- 210000002826 placenta Anatomy 0.000 claims description 23
- 239000000706 filtrate Substances 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000012528 membrane Substances 0.000 claims description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 238000001816 cooling Methods 0.000 claims description 12
- 238000009835 boiling Methods 0.000 claims description 11
- 239000012460 protein solution Substances 0.000 claims description 11
- 108091005658 Basic proteases Proteins 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 7
- 235000017784 Mespilus germanica Nutrition 0.000 claims description 7
- 244000182216 Mimusops elengi Species 0.000 claims description 7
- 235000000560 Mimusops elengi Nutrition 0.000 claims description 7
- 235000007837 Vangueria infausta Nutrition 0.000 claims description 7
- 238000001694 spray drying Methods 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 6
- 108010007119 flavourzyme Proteins 0.000 claims description 6
- 230000000415 inactivating effect Effects 0.000 claims description 6
- 238000007789 sealing Methods 0.000 claims description 6
- 238000000108 ultra-filtration Methods 0.000 claims description 6
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 5
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 5
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 5
- 108091005804 Peptidases Proteins 0.000 claims description 5
- 239000004365 Protease Substances 0.000 claims description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 5
- 229930189775 mogroside Natural products 0.000 claims description 5
- 229960003080 taurine Drugs 0.000 claims description 5
- 210000000805 cytoplasm Anatomy 0.000 claims description 4
- 210000002421 cell wall Anatomy 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 235000019534 high fructose corn syrup Nutrition 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 2
- 244000061520 Angelica archangelica Species 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 abstract description 17
- 239000002994 raw material Substances 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 25
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 13
- 229910052742 iron Inorganic materials 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 241000125175 Angelica Species 0.000 description 6
- 230000001276 controlling effect Effects 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 102000018146 globin Human genes 0.000 description 5
- 108060003196 globin Proteins 0.000 description 5
- 150000003278 haem Chemical class 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000000975 bioactive effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000593 degrading effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000272525 Anas platyrhynchos Species 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 102000003951 Erythropoietin Human genes 0.000 description 3
- 108090000394 Erythropoietin Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 229940105423 erythropoietin Drugs 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 244000241872 Lycium chinense Species 0.000 description 2
- 235000015468 Lycium chinense Nutrition 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 235000015961 tonic Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102000008015 Hemeproteins Human genes 0.000 description 1
- 108010089792 Hemeproteins Proteins 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010027540 Microcytosis Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 235000021433 fructose syrup Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a preparation method of a composite polypeptide for preventing or relieving anemia, which comprises the following steps of (1) carrying out ultrasonic crushing on a plurality of medicinal and edible plants with the function of activating blood to form plant crushing liquid, (2) adding cellulase into the plant crushing liquid for enzymolysis to obtain plant enzymolysis liquid, (3) adding plant complex enzyme into the plant enzymolysis liquid for enzymolysis to obtain micromolecule polysaccharide plant liquid, (4) adding hemoglobin powder into the micromolecule polysaccharide plant liquid, carrying out enzymolysis on the plant enzymolysis liquid to obtain micromolecule polypeptide primary liquid, (5) filtering the micromolecule polypeptide primary liquid by using a plate and frame filter to obtain polypeptide fine liquid, (6) adding auxiliary materials into the polypeptide fine liquid to obtain the composite polypeptide oral liquid or the composite polypeptide agent. The method changes the preparation method of simply adding finished hemepeptide after production and medicinal raw materials in the prior art, the composite polypeptide prepared by the method can effectively improve red blood cells, has short onset time for relieving anemia, and plays a role in preventing or relieving anemia.
Description
Technical Field
The invention relates to the field of health care products, in particular to a preparation method of a composite polypeptide for preventing or relieving anemia.
Background
Anemia is a clinical syndrome of lower than normal peripheral red blood cell volume due to various causes. The amount of hemoglobin in a volume of circulating blood by red blood cell count and the hematocrit are both below normal standards. Among them, hemoglobin is most important. According to the statistics of the world health organization: about 30 million people worldwide have different degrees of anemia. Mild anemia in adults has little effect on human bodies, but severe anemia can cause long-term blood supply insufficiency of tissues and organs, affect the functions of the tissues and the organs and possibly cause serious consequences. The number of deaths caused by anemia and various diseases is tens of millions each year. Of which about 50% of anemic patients are due to iron deficiency. Iron Deficiency Anemia (IDA), which is a kind of microcytic hypopigmentia caused by insufficient iron storage in vivo and affecting hemoglobin synthesis, is ubiquitous throughout the world, and WHO's data indicate that 30% of the global population, especially children (especially infants) and pregnant women, are affected by 50% and 40% of the total. The fourth nutrition survey in China shows that the prevalence rate of iron deficiency anemia in Chinese residents is 20.1%, wherein the prevalence rates of iron deficiency anemia in infants younger than 2 years old, elderly older than 60 years old and women of 15-50 years old are 31.1%, 29.1% and 19.9%, respectively, and the iron deficiency anemia becomes one of the most common nutritional deficiency diseases in China. Therefore, the method has important significance for the research of the prevention and treatment of the iron-deficiency anemia.
According to the research, the blood peptide can improve the red blood cell number and the hemoglobin content and has the effects of preventing and treating iron deficiency anemia. Blood peptides are mainly obtained by degrading the macromolecules of hemoglobin. Hemoglobin is a protein responsible for oxygen transport in higher organisms (Hb/HGB). Hemoglobin (Hb) is formed by the binding of globin and heme. The red color of blood is due to the presence of heme in the blood. Hemoglobin is rich in source, and the existing technology is mainly used for researching how to extract polypeptide from livestock blood, such as:
patent CN201210516085 discloses a process method for producing hemepeptide element by using pig blood, which removes impurities in the pig blood through deep filtration, and improves the purity of the hemepeptide element which is a final product.
Patent CN2012103571509 discloses a method for extracting active peptide with specific molecular weight from duck blood, which is implemented by intercepting specific active peptide through reverse osmosis ultrafiltration fractional purification, and mainly uses single-stage enzyme degradation.
Patent CN2011102863613 discloses a method for improving the yield of red blood cells of enzymolysis poultry and livestock, and special enzyme 1122 is used for single-stage degradation.
Patent CN2012103573557 discloses a process for producing small molecule hemepeptide heme iron and plasma protein by using duck blood as raw material, which mainly aims at extracting small molecule hemepeptide, heme and plasma protein through duck blood, firstly degrading by alkaline protease in the process of enzyme degradation, and then using acetic acid, ethanol and clean water for washing and purifying in the treatment process of degradation by neutral protease and flavourzyme.
The effect of the polypeptide extracted by the method is not obvious when being used alone, because the blood-enriching agent is not only required to be absorbed by a human body, but also has important effect on improving anemia. The prior art also discloses a product prepared by mixing the hemepeptide with medicinal raw materials, for example, the patent CN99125047.8 discloses a process for extracting the hemepeptide from livestock, the processing steps comprise blood collection, DC separation, primary conversion, secondary conversion, hemepeptide raw powder, preparation and product process, the cellular state is biodegraded into substances such as peptide, amino acid and the like by endopeptidase and exopeptidase to obtain the hemepeptide raw powder, and the hemepeptide raw powder is reddish brown, has slight bitter taste although no peculiar smell, and influences the taste and sense of the product. The product disclosed in this patent is a degraded hemepeptide and then formulated with a pharmaceutical material. But the final product may not taste good because of the preparation process. The prepared hemepeptide and medicinal raw materials are simply prepared, so that the active ingredients of the hemepeptide and the medicinal raw materials cannot exert more effective effects.
Disclosure of Invention
In order to achieve the above purpose, the present invention provides a method for preparing a composite polypeptide for preventing or relieving anemia, which changes the prior art of simply adding finished hemepeptide after production and medicinal raw materials, the composite polypeptide prepared by the method can effectively improve red blood cells, and the composite polypeptide has a short onset time for relieving anemia, and has the effect of preventing or relieving anemia.
In order to achieve the purpose, the invention adopts the following technical scheme:
a preparation method of a composite polypeptide for preventing or relieving anemia comprises the following preparation steps:
(1) mixing 1 part by weight of various medicinal and edible plants with the blood activating function, adding 5-15 parts by weight of water, carrying out ultrasonic disruption extraction for 2-10min under the condition of 1600-2500HZ, then cooling to 35-45 ℃, carrying out ultrasonic disruption again to achieve cell disruption and cytoplasm dissolution to form plant disruption solution;
(2) adding water into the plant crushing liquid until the solid-liquid ratio is 1:10-20, keeping the temperature to 55 ℃, adding cellulase for enzymolysis for 1-4h, and carrying out enzymolysis on plant cell walls to obtain plant enzymolysis liquid;
(3) adding plant complex enzyme into the plant enzymolysis liquid for enzymolysis for 4-10h, keeping constant temperature, boiling the solution for 5min, and inactivating enzyme to obtain micromolecular polysaccharide plant liquid;
(4) adding hemoglobin powder and deer placenta powder into small molecular polysaccharide plant liquid, adding water to 10-20 times of solid, mixing to obtain composite protein liquid, adding protease into the composite protein liquid, and performing enzymolysis to obtain small molecular polypeptide primary liquid;
(5) cooling the primary small molecular polypeptide solution to 45-65 ℃, filtering the primary small molecular polypeptide solution by using a plate and frame filter, and removing filter residues to obtain a fine polypeptide solution;
(6) adding adjuvants into the fine polypeptide filtrate, blending, sterilizing, bottling, sealing, and sterilizing at 121 deg.C under 115 deg.C to obtain composite polypeptide oral liquid or directly spray drying to obtain composite polypeptide agent.
The invention discloses a method for preparing composite polypeptide, which comprises the steps of degrading medicinal and edible plants into micromolecular polysaccharide plant liquid, adding hemoglobin powder and deer placenta powder prepared in advance, simultaneously degrading the hemoglobin powder and the deer placenta powder through enzymolysis to generate micromolecular active substances, filtering the micromolecular active substances together with the micromolecular polysaccharide plant liquid, controlling the molecular weight of all components, and ensuring that the active components can be combined with each other.
Compared with the prior art, the invention has the following beneficial effects:
1. the composite polypeptide consists of three parts: the deer placenta powder promotes blood circulation, increases absorption of organisms, and the micromolecular polysaccharide plant liquid supplements qi and blood, can realize multidirectional matching, prevents anemia, and can quickly relieve anemia symptoms.
2. The hemoglobin powder and the deer placenta powder are subjected to enzymatic degradation simultaneously, so that reaction steps are reduced, degradation effects are unified, molecular weight is controlled in a similar range after filtration, the hemoglobin powder and the deer placenta powder are easy to absorb by a human body, and effects of each other are enhanced.
Detailed Description
The present invention will be described in further detail below by way of specific embodiments:
a preparation method of a composite polypeptide for preventing or relieving anemia comprises the following preparation steps:
(1) mixing 1 part by weight of various medicinal and edible plants with the blood activating function, adding 5-15 parts by weight of water, carrying out ultrasonic disruption extraction for 2-10min under the conditions of 1600-2500HZ, then cooling to 35-45 ℃, carrying out ultrasonic disruption again to achieve cell disruption and cytoplasm dissolution to form plant disruption solution;
(2) adding water into the plant crushing liquid until the solid-liquid ratio is 1:10-20, keeping the temperature to 55 ℃, adding cellulase for enzymolysis for 1-4h, and carrying out enzymolysis on plant cell walls to obtain plant enzymolysis liquid;
(3) adding plant complex enzyme into the plant enzymolysis liquid for enzymolysis for 4-10h, keeping constant temperature, boiling the solution for 5min, and inactivating enzyme to obtain micromolecular polysaccharide plant liquid;
(4) adding hemoglobin powder and deer placenta powder into small molecular polysaccharide plant liquid, adding water to 10-20 times of solid, mixing to obtain composite protein liquid, adding protease into the composite protein liquid, and performing enzymolysis to obtain small molecular polypeptide primary liquid;
(5) cooling the primary small molecular polypeptide solution to 45-65 ℃, filtering the primary small molecular polypeptide solution by using a plate and frame filter, and removing filter residues to obtain a fine polypeptide solution;
(6) adding adjuvants into the fine polypeptide filtrate, blending, sterilizing, bottling, sealing, and sterilizing at 121 deg.C under 115 deg.C to obtain composite polypeptide oral liquid or directly spray drying to obtain composite polypeptide agent.
The various medicinal and edible plants with the function of promoting blood circulation in the step (1) comprise the following components in percentage by dry weight: 10 to 30 percent of angelica, 30 to 50 percent of red date, 20 to 50 percent of medlar and 10 to 30 percent of rhizoma polygonati.
The weight of the cellulase added in the step (2) is 2-7% calculated according to the dry weight of the medicinal and edible plants.
The weight of the plant complex enzyme added in the step (3) is 5-10% according to the dry weight of the medicinal and edible plants.
The weight of the added hemoglobin and the deer placenta powder in the step (4) is 1-5 times of the weight of the medicinal and edible plant according to the dry weight of the medicinal and edible plant, wherein the weight ratio of the hemoglobin powder to the deer placenta powder is 5-10: 1.
the enzymolysis in the step (4) comprises the following specific steps: adding NaOH into the composite protein solution, adjusting the pH value to 9.0, placing the solution in a constant temperature environment of 60 ℃, adding 0.1-0.5% of alkaline protease calculated by dry matters, maintaining for 2-6h, adjusting the pH value of the composite protein solution subjected to alkaline protease enzymolysis to 7.0, adding 0.03-0.1% of flavourzyme calculated by dry matters in a constant temperature environment of 50 ℃, performing enzymolysis for 0.5-1 h, boiling, maintaining for 2-5min, and inactivating enzyme to obtain the required primary micromolecule polypeptide solution.
The filtration comprises the following specific steps: and (3) filtering the primary filtrate of the composite polypeptide by an ultrafiltration membrane, wherein the interception amount of membrane molecules is 1-5 ten thousand Da, and treating by using a 1-2KDa membrane after the treatment is finished.
The auxiliary materials comprise the following components in percentage by volume of the polypeptide fine filtrate: 0.11g/L taurine, 2-10g/L high fructose corn syrup and 0.05-0.1g/L mint.
The auxiliary materials are calculated according to the volume of the polypeptide fine filtrate, and the auxiliary materials further comprise: 0.1 to 1 percent of mogroside and 0.1 to 0.8 thousandth of edible essence.
Deer placenta: the deer placenta and deer fetus have the efficacies of tonifying kidney and yang, and tonifying deficiency and producing sperm in traditional Chinese medicine, and are also commonly used as tonics in folk. Modern researches show that the placenta contains protein, gonadotropin, prolactin, lysozyme, polysaccharide, urokinase, various mineral elements, vitamins and the like, has various functions of promoting growth, promoting lactation, improving immunity and the like, has good regulating effect on female ovaries, and is an ideal immunomodulator and a nutritional health-care product. The small molecular polypeptide is formed after the enzymolysis, female hormone is regulated, ovary maintenance is facilitated, anemia can be promoted to be relieved, and the effect on female anemia is good.
Chinese angelica root: enriching the blood; promoting blood circulation; regulating menstruation and relieving pain; moistening dryness and smoothing intestine. The main symptoms are blood deficiency; menoxenia; amenorrhea; dysmenorrhea; the symptoms are accumulated; (ii) metrorrhagia and metrostaxis; abdominal pain due to deficiency-cold; flaccidity and paralysis; numbness of the skin; intestinal dryness and difficult defecation; severe dysentery with diarrhea; carbuncle, cellulitis, sore and ulcer; injury from falling.
Red dates: the red dates are sweet in taste and warm in nature, have the functions of tonifying middle-jiao and Qi, nourishing blood and tranquilization and moderating drug properties, and have the spleen and stomach channels. Modern pharmacological research finds that the red dates can increase the oxygen content in blood and nourish cells of the whole body, and are a tonic with mild medicinal effect.
Medlar: nourish liver, nourish kidney, moisten lung. Wolfberry leaf: tonify deficiency and replenish vital essence, clear heat and improve eyesight.
Rhizoma polygonati: invigorating qi, nourishing yin, invigorating spleen, moistening lung, and invigorating kidney; can be used for treating deficiency of spleen-stomach qi, asthenia, stomach yin deficiency, xerostomia, cough with little appetite, lung deficiency, cough with excessive consumption, hemoptysis, essence and blood deficiency, soreness of waist and knees, premature gray hair, and internal heat with thirst quenching effect.
Pig hemoglobin: the bioactive peptide with pig blood as protein source is produced through converting globin in pig blood into small molecular peptide. The small molecular pig blood peptide not only has good dissolubility, low viscosity and gel formation resistance, but also is quickly digested and absorbed in vivo. The oligopeptide consisting of 2-3 amino acids has better absorption performance than free amino acids, and the oligopeptide and the polypeptide in the diet can be completely absorbed through intestinal tracts and used as bioactive peptides to cause biological effects of organisms on the tissue level. In addition, the composition has low antigenicity, does not produce anaphylactic reaction, has physiological activity of fat metabolism and the like, so that pig blood is utilized to decompose hemoglobin in blood cells into globin and heme, the globin is further subjected to enzymolysis to obtain peptide substances with biological activity, and the composition is proved to have the effects of quickly treating and improving anemia through a white mouse experiment. The micromolecule polypeptide formed by the enzymolysis of the hemoglobin can be combined with free iron of a human body in time to form red blood cells and improve anemia symptoms.
The invention utilizes the principle of traditional Chinese medicine to carry out cell disruption and enzymolysis on medlar, red dates, sealwort, angelica and other substances with the functions of activating blood and enriching blood, and then carries out enzymolysis together with hemoglobin and deer placenta to obtain the compound polypeptide substance. The Chinese wolfberry, the red dates, the sealwort, the angelica and other substances have the functions of tonifying the kidney and helping nutrient substances to be absorbed, meanwhile, the active substances and the hemoglobin are subjected to enzymolysis together, and when the composite polypeptide is formed, the small molecular active ingredients are combined with the hemoglobin, so that the formation of the human body neohemoglobin is facilitated, and the anemia problem is helped to be treated and treated.
The hemoglobin powder can be prepared by the following method:
s1, dissolving: pouring the pig hemoglobin into an enzymolysis tank, adding purified water with the weight 5-15 times that of the pig hemoglobin, and fully stirring and dissolving.
S2, enzymolysis: adding alkaline protease accounting for 2-6% of the dry weight of the porcine hemoglobin, performing enzymolysis for 2-8 hours, and simultaneously controlling the temperature in an enzymolysis reaction tank to be 40-60 ℃ and the pH value to be 6.5-8.5;
s3, filtering: heating materials in an enzymolysis reaction tank to boil, then slightly boiling for 5-15 minutes to inactivate protease, cooling the enzymolysis reaction tank to 45-65 ℃, filtering the materials by adopting a plate and frame filter, and removing filter residues to obtain a blood peptide solution;
s4, decoloring step: adding activated carbon with the weight being 4-10% of the dry weight of the porcine hemoglobin into the filtered filtrate, fully stirring, controlling the temperature in an enzymolysis reaction tank to be 60-90 ℃, controlling the pH value to be 3-6, decoloring for 1-3 hours, then adjusting the pH value, and filtering;
s5, concentration step: introducing the filtered filtrate into a scraper evaporator according to the flow of 800kg/h, and carrying out vacuum concentration treatment at the temperature of 60-75 ℃ to obtain decolorized blood peptide feed liquid with the concentration of 40-50%;
s6, spray drying: and (4) carrying out spray drying on the decolorized blood peptide concentrated solution to obtain decolorized hemoglobin powder.
The preparation method of the composite polypeptide for preventing or relieving anemia disclosed by the invention has the following advantages:
the active peptide obtained by protein enzymolysis has good effect of relieving anemia. In addition, the source of the pig blood is rich, and the production of the bioactive peptide by using the pig blood is necessary. The bioactive peptide with pig blood as protein source is produced through converting globin in pig blood into small molecular peptide. The small molecular pig blood peptide not only has good dissolubility, low viscosity and gel formation resistance, but also is fast to digest and absorb in vivo, and has low antigenicity, no anaphylactic reaction, fat metabolism and other physiological activities. The blood peptide is supplemented with medicinal and edible materials such as angelica, red date, medlar and the like which have the functions of promoting blood circulation and removing blood stasis, and the composite polypeptide oral liquid and the composite polypeptide preparation are processed. The composite polypeptide agent and the composite polypeptide oral liquid for preventing or relieving anemia are simple to process, stable in taste, obvious in effect and free of adverse effects, and are good functional foods.
The blood peptide in the composite polypeptide disclosed by the invention is firstly subjected to enzymolysis by the haemoglobin to form macromolecular polypeptide, and then the deer placenta powder and the medicine-food homologous plant for improving anemia are added for joint enzymolysis, so that the composite polypeptide agent has better effects of preventing and relieving anemia. The small molecular active ingredients of medlar, red dates, sealwort, angelica and the like are utilized to enhance the kidney absorption effect and the blood circulation promoting effect; the deer placenta polypeptide and the blood peptide are utilized to enhance the free iron complexing ability of hemoglobin in vivo and increase the number and activity of hemoglobin in vivo, and the anemia improving effect is obvious.
Example 1 preparation of hemoglobin:
s1, dissolving: 2kg of pig hemoglobin is poured into an enzymolysis tank, 18kg of purified water is added, and the mixture is fully stirred and dissolved.
S2, enzymolysis: adding 80g of alkaline protease, carrying out enzymolysis for 3 hours, and simultaneously controlling the temperature in an enzymolysis reaction tank to be 60 ℃ and the pH value to be 8.0;
s3, filtering: heating materials in an enzymolysis reaction tank to boil, then boiling for 10 minutes slightly to inactivate protease, cooling the enzymolysis reaction tank to 50 ℃, then filtering the materials by adopting a plate-and-frame filter, and removing filter residues to obtain a blood peptide solution;
s4, decoloring step: adding 160g of active carbon into the filtered filtrate, fully stirring, controlling the temperature in an enzymolysis reaction tank to be 80 ℃ and the pH value to be 4.8, decoloring for 1 hour, then adjusting the pH value, and filtering;
s5, concentration step: introducing the filtered filtrate into a scraper evaporator according to the flow of 800kg/h, and performing vacuum concentration treatment at 60 ℃ to obtain decolorized blood peptide feed liquid with the concentration of 40-50%;
s6, spray drying: spray drying the decolorized blood peptide concentrated solution to obtain decolorized hemoglobin powder.
Example 2 composite polypeptide preparation:
1. adding 500g of angelica, 1500g of red date, 2500g of medlar and 1000g of rhizoma polygonati according to dry matter, and adding 22.5kg of purified water. And (5) carrying out ultrasonic treatment for 10min under the ultrasonic condition of 2000 HZ. Cooling to 40 deg.C, performing ultrasonic treatment for 1 time under the same conditions, crushing material cells, and dissolving out cytoplasm to obtain plant crushed solution.
2. Adding pure water into the plant crushing liquid until the solid-liquid ratio is 1:10, keeping the temperature to 55 ℃, adding 225g of cellulase, and carrying out enzymolysis for 3h to obtain plant enzymolysis liquid; adding 360g of plant complex enzyme into the plant enzymolysis liquid, carrying out enzymolysis for 7h, and keeping the constant temperature. Boiling the solution for 5min, inactivating enzyme, and preparing into small molecular polysaccharide plant liquid.
3. After the temperature of the micromolecular polysaccharide plant liquid is reduced, 3760g of hemoglobin powder and 740g of deer placenta powder are added, and 67.5kg of purified water is added to prepare the compound protein liquid.
4. Adding NaOH into the composite protein solution, adjusting the pH value to 9.0, placing the solution in a constant temperature environment of 60 ℃, adding 27g of alkaline protease, and maintaining for 3 hours.
5. Adjusting the pH value of the composite protein liquid subjected to alkaline enzymolysis to 7.0, adding 45g of flavourzyme in a constant temperature environment at 50 ℃, carrying out enzymolysis for 0.5h, boiling and maintaining for 5min to inactivate enzyme, thus obtaining the required primary micromolecule polypeptide liquid.
6. And (3) cooling the primary small molecular polypeptide solution to 45 ℃, then filtering the material by adopting a plate and frame filter, and removing filter residues to obtain the primary filter solution of the composite polypeptide.
7. And (3) passing the primary filtrate of the composite polypeptide through an ultrafiltration membrane, wherein the membrane molecular interception amount is 1WDa, treating by using a 1KDa membrane after the treatment, concentrating and filtering to prepare the composite polypeptide liquid which is high in concentration, small in molecular weight and capable of preventing and relieving anemia to a certain extent. The membrane filtration can effectively remove macromolecules, micromolecule bitter amino acids and decoloration.
8. Adding 9.9g taurine, 450g high fructose corn syrup, 5.4g mint, 960g mogroside and 48g edible essence auxiliary materials into the composite polypeptide liquid, filling and sealing, and sterilizing at 115 ℃ and 20Min to prepare the composite polypeptide for preventing and relieving anemia.
Comparative example 1:
the polypeptide preparation is prepared by only using the hemoglobin powder without adding the plant composite enzymolysis liquid and the deer placenta powder, and comprises the following specific steps:
1. adding purified water into hemoglobin powder until the dry matter is 10 times, and preparing protein solution.
2. Adding NaOH into the protein solution, adjusting pH to 9.0, placing the solution in a constant temperature environment of 60 deg.C, adding alkaline protease with dry matter content of 0.3%, and maintaining for 3 hr.
3, adjusting the pH value of the protein solution subjected to alkaline enzymolysis to 7.0, adding 0.05% flavourzyme of dry matter (based on the initial mass of the compound) into a constant temperature environment of 50 ℃, carrying out enzymolysis for 0.5h, boiling and maintaining for 5min to inactivate enzyme, thus obtaining the required primary micromolecule polypeptide solution.
4. And (3) cooling the primary small molecular polypeptide solution to 45 ℃, then filtering the material by adopting a plate and frame filter, and removing filter residues to obtain the primary polypeptide filtrate.
5. And (3) passing the primary filtrate of the polypeptide through an ultrafiltration membrane, treating the primary filtrate by using a 1KDa membrane after the primary filtrate of the polypeptide is treated by using a membrane with the membrane molecular interception amount of 1WDa, and concentrating and filtering.
6. Adding 0.11g/L taurine, 5g/L fructose-glucose syrup, 0.06g/L mint, 1% mogroside and 0.5 ‰ edible essence as adjuvants into the polypeptide liquid, bottling, sealing, sterilizing at 115 deg.C and 20Min, and making into polypeptide preparation.
Comparative example 2:
directly using hemoglobin powder and deer placenta powder for enzymolysis to prepare the compound polypeptide agent, and adding no plant compound enzymolysis liquid. The method comprises the following specific steps:
1. adding purified water into hemoglobin powder and deer placenta powder (at a dry weight ratio of 5: 1), and making into compound protein solution by 10 times of dry matter.
2. Adding NaOH into the composite protein solution, adjusting pH to 9.0, placing the solution in a constant temperature environment of 60 ℃, adding alkaline protease with dry matter content of 0.3%, and maintaining for 3 h.
3, adjusting the pH value of the compound protein solution subjected to alkaline enzymolysis to 7.0, adding 0.05% flavourzyme of dry matter (according to the initial mass of the compound) into a constant temperature environment of 50 ℃, carrying out enzymolysis for 0.5h, boiling and maintaining for 5min to inactivate enzyme, thus obtaining the required primary micromolecular polypeptide solution.
4. And (3) cooling the primary small molecular polypeptide solution to 45 ℃, then filtering the material by adopting a plate and frame filter, and removing filter residues to obtain the primary polypeptide filtrate.
5. And (3) passing the primary filtrate of the polypeptide through an ultrafiltration membrane, treating the primary filtrate by using a 1KDa membrane after the primary filtrate of the polypeptide is treated by using a membrane with the membrane molecular interception amount of 1WDa, and concentrating and filtering.
6. Adding 0.11g/L taurine, 5g/L high fructose syrup, 0.06g/L mint, 1% mogroside and 0.5 ‰ edible essence adjuvant into polypeptide liquid, bottling, sealing, sterilizing at 115 deg.C for 20Min, and making into pre-polypeptide preparation.
The effect of the comparative test is shown as follows:
after three days of acclimatization of SD rats with basal diet and normal drinking water, model-making rats (A, B, C, D, F) were changed to low-iron diet supplemented with deionized water and normal control rats (E) were kept unchanged. The drug administration of the model rats is started after the hemoglobin content is generally lower than 100g/L (namely, the model is anemia). Once daily dosing schedule and doses for each group are shown in table 1. Erythropoietin (EPO) feed was used as a drug positive control for the treatment of anemia. And collecting blood samples in a tail shearing mode every week, and performing anticoagulation by adopting a 2.5% EDTA-2Na solution in a volume ratio of 1:9 to finish routine blood detection. The effect of the complex polypeptide agent of the present invention on amelioration and treatment of anemia was determined according to the 1 month feeding period.
Wherein the low-iron feed (the iron content is 8.4mg/kg, purchased from Beijing Borai Macroda biotechnology limited); basal feed (Silekang rat breeder, available from Shanghai Proteus Biotech Co., Ltd.).
The number of red blood cells in normal rat is 5.6X 1012The normal range of the hemoglobin content is 120 g/L; the anemia reference line is the number of red blood cells 4.7X 1012The range of the hemoglobin content anemia is lower than 120 g/L.
Table 1: compound polypeptide feeding condition of mice
Comparative effect result 1:
comparing the number of red blood cells in the routine blood feeding of rats for 1 month with that in the following table 2, the red blood cells in the normal group have a normal reference value range of not less than 5.6 × 1012L, after feeding normal feed, the number of red blood cells does not greatly fluctuate at normal value within one month; anemia group (number of rat red blood cells is less than or equal to 4.7 multiplied by 10)12L), feeding low-iron feed and feeding with deionized water, and administering EPO for treating anemia to group F, wherein the red blood cells of the rat are obviously increased in 1 week and recovered to normal value in 2 weeks, and then feeding is continued, and the red blood cell number is obviously increased; when the group D is fed with normal saline and low-iron feed, the number of red blood cells of a rat is always reduced, and the anemia condition is more and more serious; when the group A is fed with the compound polypeptide agent and the low-iron feed, the normal level is basically recovered at the 2 nd week of feeding, the anemia state is improved, which is slightly lower than that of drug treatment and is obviously higher than that of the B, C two groups. When the group B is fed with the polypeptide agent and the low-iron feed of the comparative example 1, the normal level is basically recovered at week 3, the anemia state is improved, and the effect is lower than that of the group A; group C was fed with the polypeptide agent of comparative example 2 plus low iron feed, and at week 3, the level was substantially restored to normal, and the anemia state was improved, with less effect than group A.
TABLE 2 comparison of the erythrocyte content for the results of the tests
The comparative experiment shows that the content of the active ingredients,
1. the compound polypeptide agent disclosed by the invention has the effects of treating and relieving anemia similar to those of medicines;
2. according to the compound polypeptide preparation disclosed by the invention, the added medicinal and edible plants are subjected to enzymolysis together, so that the anemia relieving effect of the compound polypeptide is enhanced; mainly shows that the effect of relieving the anemia is stably improved, and is more approximate to the therapeutic effect of the medicine compared with the polypeptide without medicine-food homology.
3. The composite polypeptide agent disclosed by the invention has the advantages that the added deer placenta is subjected to enzymolysis together, so that the effect of relieving anemia of the composite polypeptide agent is enhanced, the effect is fast, and the relieving level is stable.
Finally, the above embodiments are only for illustrating the technical solutions of the present invention and not for limiting, although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions may be made to the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention, and all of them should be covered in the claims of the present invention.
Claims (6)
1. A preparation method of a composite polypeptide for relieving anemia is characterized in that: the preparation method comprises the following steps:
(1) mixing 1 part by weight of various medicinal and edible plants with the function of activating blood, adding 5-15 parts by weight of water, carrying out ultrasonic disruption extraction for 2-10min under the conditions of 1600-2500HZ, then cooling to 35-45 ℃, carrying out ultrasonic disruption again to achieve cell disruption and cytoplasm dissolution to form plant disruption solution;
(2) adding water into the plant crushing liquid until the solid-to-liquid ratio is 1:10-20, keeping the temperature to 55 ℃, adding cellulase for enzymolysis for 1-4h, and carrying out enzymolysis on plant cell walls to obtain plant enzymolysis liquid;
(3) adding plant complex enzyme into the plant enzymolysis liquid for enzymolysis for 4-10h, keeping constant temperature, boiling the solution for 5min, and inactivating enzyme to obtain micromolecular polysaccharide plant liquid;
(4) adding hemoglobin powder and deer placenta powder into small molecular polysaccharide plant liquid, adding water to 10-20 times of solid, mixing to obtain composite protein liquid, adding protease into the composite protein liquid, and performing enzymolysis to obtain small molecular polypeptide primary liquid;
(5) cooling the primary small molecular polypeptide solution to 45-65 ℃, filtering the primary small molecular polypeptide solution by using a plate and frame filter, and removing filter residues to obtain a fine polypeptide solution;
(6) adding auxiliary materials into the polypeptide fine filtrate, blending, sterilizing, filling and sealing, and then sterilizing at the temperature of 115 ℃ and 121 ℃ to obtain a composite polypeptide oral liquid or directly spray-drying to obtain a composite polypeptide agent;
the various medicinal and edible plants with the blood activating function in the step (1) comprise the following medicinal and edible plants in terms of dry weight: 10 to 30 percent of angelica, 30 to 50 percent of red date, 20 to 50 percent of medlar, 10 to 30 percent of rhizoma polygonati,
the weight of the added hemoglobin and the deer placenta powder in the step (4) is 1-5 times of the weight of the medicinal and edible plant according to the dry weight of the medicinal and edible plant, wherein the weight ratio of the hemoglobin powder to the deer placenta powder is 5-10: 1;
the enzymolysis in the step (4) comprises the following specific steps: adding NaOH into the composite protein solution, adjusting the pH value to 9.0, placing the solution in a constant temperature environment of 60 ℃, adding 0.1-0.5% of alkaline protease calculated by dry matters, maintaining for 2-6h, adjusting the pH value of the composite protein solution subjected to alkaline protease enzymolysis to 7.0, adding 0.03-0.1% of flavourzyme calculated by dry matters in a constant temperature environment of 50 ℃, performing enzymolysis for 0.5-1 h, boiling, maintaining for 2-5min, and inactivating enzyme to obtain the required primary micromolecule polypeptide solution.
2. The method for preparing a complex polypeptide for alleviating anemia according to claim 1, wherein: the weight of the cellulase added in the step (2) is 2-7% calculated according to the dry weight of the medicinal and edible plants.
3. The method for preparing a complex polypeptide for alleviating anemia according to claim 1, wherein: the weight of the plant complex enzyme added in the step (3) is 5-10% according to the dry weight of the medicinal and edible plants.
4. The method for preparing the composite polypeptide for relieving anemia according to claim 1, wherein the method comprises the following steps: the filtration comprises the following specific steps: and (3) passing the primary filtrate of the composite polypeptide through an ultrafiltration membrane, wherein the membrane molecular interception amount is 1-5 ten thousand Da, and treating by using a 1-2KDa membrane after the treatment is finished.
5. The method for preparing the composite polypeptide for relieving anemia according to claim 1, wherein the method comprises the following steps: the auxiliary materials comprise the following components in percentage by volume of the polypeptide fine filtrate: 0.11g/L taurine, 2-10g/L high fructose corn syrup and 0.05-0.1g/L mint.
6. The method for preparing the composite polypeptide for relieving anemia according to claim 5, wherein: the auxiliary materials are calculated according to the volume of the polypeptide fine filtrate, and the auxiliary materials further comprise: 0.1 to 1 percent of mogroside and 0.1 to 0.8 thousandth of edible essence.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910186658.9A CN109793885B (en) | 2019-03-13 | 2019-03-13 | Preparation method of composite polypeptide for preventing or relieving anemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910186658.9A CN109793885B (en) | 2019-03-13 | 2019-03-13 | Preparation method of composite polypeptide for preventing or relieving anemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109793885A CN109793885A (en) | 2019-05-24 |
| CN109793885B true CN109793885B (en) | 2022-07-08 |
Family
ID=66562827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910186658.9A Active CN109793885B (en) | 2019-03-13 | 2019-03-13 | Preparation method of composite polypeptide for preventing or relieving anemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109793885B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110934837B (en) * | 2019-12-16 | 2021-10-22 | 西藏天虹科技股份有限责任公司 | Polygonatum sibiricum polypeptide composite tablet and preparation method thereof |
| CN113304244A (en) * | 2021-05-26 | 2021-08-27 | 杭州佰倍优生物科技有限公司 | Preparation method of blood protein polypeptide for preventing and relieving anemia |
| CN115462524A (en) * | 2022-08-29 | 2022-12-13 | 杭州佰倍优生物科技有限公司 | A blood peptide with skin caring and antiaging effects, and its preparation method |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1543987A (en) * | 2003-11-18 | 2004-11-10 | 吉林大学 | Preparing process and application of active peptide-Lutaisu by making use of spotted deer placenta |
| CN108148881A (en) * | 2017-12-29 | 2018-06-12 | 浦江县美泽生物科技有限公司 | The preparation method of hemoglobin polypeptide powder |
-
2019
- 2019-03-13 CN CN201910186658.9A patent/CN109793885B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1543987A (en) * | 2003-11-18 | 2004-11-10 | 吉林大学 | Preparing process and application of active peptide-Lutaisu by making use of spotted deer placenta |
| CN108148881A (en) * | 2017-12-29 | 2018-06-12 | 浦江县美泽生物科技有限公司 | The preparation method of hemoglobin polypeptide powder |
Non-Patent Citations (1)
| Title |
|---|
| 胎盘的有效成分及其应用;张淑二等;《动物医学进展》;20070920(第09期);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109793885A (en) | 2019-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109793885B (en) | Preparation method of composite polypeptide for preventing or relieving anemia | |
| CN101618206B (en) | Composition for sobering up and protecting liver | |
| CN107998333B (en) | Preparation method of donkey-hide gelatin peptide product | |
| CN112772813A (en) | Compound peptide solid beverage capable of improving immunity and relieving fatigue and preparation method thereof | |
| CN101721458A (en) | Method for preparing human placenta tissue fluid | |
| CN107164446A (en) | The preparation method and its antifatigue effect of deer hemepeptide | |
| CN111387397A (en) | Bovine bone peptide beverage for improving skeleton and preparation method thereof | |
| CN112971151A (en) | Ginseng and walnut peptide composition capable of improving immunity and preparation method thereof | |
| CN101647816B (en) | Bionic enzymatic hydrolysate for animal skins and application thereof | |
| CN111743165A (en) | Food composition for resisting fatigue and enhancing male functions and preparation method thereof | |
| CN104739964B (en) | A kind of snail sobering preparation and preparation method thereof | |
| CN110960554A (en) | Selenium-rich oyster sea cucumber tablet and preparation method thereof | |
| CN109457009B (en) | Preparation method of micromolecule astragalus membranaceus chelating peptide | |
| CN114010750A (en) | Ginseng and grass formula for tonifying kidney, generating blood and resisting aging | |
| CN113068784A (en) | SOD beverage for relieving body pain and preparation method thereof | |
| CN113598377A (en) | Composition for improving anemia, functional food thereof, preparation method and application | |
| CN114404433B (en) | Pinoresinol diglucoside composition for improving microcirculation and preparation method thereof | |
| CN103610116A (en) | Preparation method for sea cucumber nutritional capsule | |
| CN108095111B (en) | Nutritional composition containing deep seawater minerals and its application in promoting lactation after delivery | |
| CN112790391A (en) | Micromolecule oligopeptide powder composition and preparation method and application thereof | |
| CN117384980A (en) | Burdock L-arginine fermentation process for promoting male sexual function improvement | |
| CN111778129A (en) | Nucleic acid and amino acid health oral liquid and preparation method thereof | |
| CN1350860A (en) | Process for preparing health-care oral liquid for diabetics | |
| CN117431132A (en) | Preparation method of health care wine | |
| CN117598491A (en) | Preparation method of ginseng peptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231225 Address after: Room 703, Building 7, No. 601 Qiuyi Road, Changhe Street, Binjiang District, Hangzhou City, Zhejiang Province, 310000 Patentee after: Hangzhou Egg White Technology Co.,Ltd. Address before: No.195 Dongfang Avenue, Jingzhou Development Zone, Hubei Province, 434000 Patentee before: HUBEI REBORN BIOTECH CO.,LTD. |
|
| TR01 | Transfer of patent right |